JPMorgan expects shares of MAP Pharmaceuticals to trade higher today after the company announced that the Levadex resubmission has been accepted by the FDA with a six-month review. The firm continues to expect approval for Levadex and maintains an Overweight rating on the stock.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?